内科

目的探讨高通量血液透析（HFHD）对维持性血液透析患者肾功能、钙磷代谢及营养状况的影响。方法选择2018年1月至2019年12月在我院行维持性血液透析治疗的患者120例，采用随机数字法分为两组，每组60例。对照组患者给予低通量血液透析（LFHD）治疗，研究组患者给予HFHD治疗，疗程6个月。比较两组患者治疗前后的肾功能、血清钙磷水平和营养状况。结果治疗前，两组患者的血肌酐（Scr）、血尿素氮（BUN）水平比较，差异无统计学意义（P＞0.05）；治疗6个月后，两组患者的Scr、BUN水平均显著降低，研究组患者的水平显著低于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者的血清钙、磷水平比较，差异无统计学意义（P＞0.05）；治疗6个月后，研究组患者的血清钙水平明显增高并显著高于对照组，血清磷水平明显降低并显著低于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者的体质量指数（BMI）、白蛋白（ALB）及转铁蛋白（TF）水平比较，差异无统计学意义（P＞0.05）；治疗6个月后，两组患者的BMI、ALB、TF水平均显著升高，研究组患者的水平显著高于对照组，差异有统计学意义（P＜0.05）。结论高通量血液透析治疗能显著改善维持性血液透析患者的肾功能、钙磷代谢水平及营养状况，值得推广应用。

ObjectiveTo explore the effects of high flux hemodialysis (HFHD) on renal function, calcium-phosphorus metabolism and nutritional status in maintenance hemodialysis patients. MethodsA total of 120 patients who underwent maintenance hemodialysis in our hospital from January 2018 to December 2019 were selected and divided into two groups by the random number method, with 60 cases in each group. Patients in the control group were treated with low flux hemodialysis (LFHD), whereas patients in the study group were treated with HFHD, for a six-month treatment course. The renal function, serum calcium-phosphorus levels and nutritional status were compared between the two groups before and after treatment. ResultsThere were no statistically significant differences in serum creatinine (Scr) and blood urea nitrogen (BUN) levels between the two groups before treatment (P＞0.05). After 6 months of treatment, the Scr and BUN levels of the two groups significantly decreased, and the levels in the study group were significantly lower than those in the control group, with statistically significant differences (P＜0.05). There were no statistically significant differences in the serum calcium-phosphorus levels of the two groups before treatment (P＞0.05). After 6 months of treatment, the serum calcium level of the study group significantly increased, which was significantly higher than that of the control group, whereas the serum phosphorus level significantly decreased, which was significantly lower than that of the control group, with statistically significant differences (P＜0.05). There were no statistically significant differences in the body mass index (BMI), albumin (ALB) and transferrin (TF) levels of the two groups before treatment (P＞0.05). After 6 months of treatment, the BMI, ALB, and TF levels of the two groups increased significantly, and the levels of the study group were significantly higher than those of the control group (P＜0.05). ConclusionHFHD can prominently improve the renal function, calcium-phosphorus metabolism levels and nutritional status in maintenance hemodialysis patients, which is worthy of promotion and application.